Member
Providers
Shop For a Plan

The Fidelis Care Blog


Fidelis Care Authorization Grids Effective October 1, 2022
9/1/2022 • Posted by Provider Relations in Provider News

The following sections of the Fidelis Care authorization grids have been updated effective October 1, 2022.

 

The Essential Plan, Medicaid, Medicare and Metal-Level Products grids have been updated as follows:

 

V.         Outpatient and DME Services: The following services require prior authorization:                                      

A.    Diagnostic testing:                                                                                                          

2.   Breast Cancer testing (BRCA) and other Genetic Testing (Note: Authorization is not required for CPT 81220, 81329, 81336 and 81420.  CPT 81220 has a lifetime limit of 1. CPT 81329 and 81336 have a combined limit of 1 per lifetime.)                                                                                                                     

 

The following codes have been updated on the Essential Plan, Medicaid, Medicare and Metal-Level Products grids and require prior authorization:

 

C9142 bevacizumab-maly (Alymsys)

J1302  sutimlimab-jome (Enjaymo)

J1932  lanreotide

J2777  faricimab-svoa (Vabysmo)

J9274  tebentafusp-tebn (Kimmtrak)

J9298  nivolumab and relatlim a b-rmbw (Opduakag)

Q2056 ciltacabtagene autoleuce (Carvykti)

Q5125 filgrastim-ayow, biosimilar, (Releuko)

 

The following codes have been added to the Medicaid DME authorization grid and require prior authorization:

 

           

A4232

L1852

L3550

L5718

L7400

A7046

L2200

L3560

L5782

L7401

B4105

L2240

L3590

L5848

L7402

E0484

L3001

L3595

L5859

L7403

E2301

L3031

L3761

L5961

L7404

K1013

L3500

L4392

L6647

L7405

K1022

L3510

L4394

L6648

L7700

L0859

L3520

L5616

L6715

 

L1851

L3530

L5617

L6880

 

 

 

Visit:  Authorization Grids

 

COVID-19 UPDATE: Please refer to this link:  Important Updates Regarding Coronavirus COVID-19, for authorization and coding guidelines related to the COVID-19 Pandemic.

 

 

Smiles-that-Shine

 

Looking for Information on a Specific Health Topic?

Doctor-Checklist-Animation


Fidelis Care Authorization Grids Effective October 1, 2022
9/1/2022 • Posted by Provider Relations

The following sections of the Fidelis Care authorization grids have been updated effective October 1, 2022.

 

The Essential Plan, Medicaid, Medicare and Metal-Level Products grids have been updated as follows:

 

V.         Outpatient and DME Services: The following services require prior authorization:                                      

A.    Diagnostic testing:                                                                                                          

2.   Breast Cancer testing (BRCA) and other Genetic Testing (Note: Authorization is not required for CPT 81220, 81329, 81336 and 81420.  CPT 81220 has a lifetime limit of 1. CPT 81329 and 81336 have a combined limit of 1 per lifetime.)                                                                                                                     

 

The following codes have been updated on the Essential Plan, Medicaid, Medicare and Metal-Level Products grids and require prior authorization:

 

C9142 bevacizumab-maly (Alymsys)

J1302  sutimlimab-jome (Enjaymo)

J1932  lanreotide

J2777  faricimab-svoa (Vabysmo)

J9274  tebentafusp-tebn (Kimmtrak)

J9298  nivolumab and relatlim a b-rmbw (Opduakag)

Q2056 ciltacabtagene autoleuce (Carvykti)

Q5125 filgrastim-ayow, biosimilar, (Releuko)

 

The following codes have been added to the Medicaid DME authorization grid and require prior authorization:

 

           

A4232

L1852

L3550

L5718

L7400

A7046

L2200

L3560

L5782

L7401

B4105

L2240

L3590

L5848

L7402

E0484

L3001

L3595

L5859

L7403

E2301

L3031

L3761

L5961

L7404

K1013

L3500

L4392

L6647

L7405

K1022

L3510

L4394

L6648

L7700

L0859

L3520

L5616

L6715

 

L1851

L3530

L5617

L6880

 

 

 

Visit:  Authorization Grids

 

COVID-19 UPDATE: Please refer to this link:  Important Updates Regarding Coronavirus COVID-19, for authorization and coding guidelines related to the COVID-19 Pandemic.